Compared to women 36–50 years of age, those ≤35 years of age had a higher proportion of HER2 tumours (24.58% vs. 16.94%; p = 0.021), PR-(29.85% vs. 22.95%; p = 0.043), and stage 3 disease (29.34% vs. 18.52%; p < 0.001) [208]. The gene discussed is PGR; the disease is neoplasm.